Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas (IRUSZACT0073)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00822887|
Recruitment Status : Completed
First Posted : January 15, 2009
Last Update Posted : June 26, 2013
The purpose of the study is to find out the highest dose of vandetanib that can be safely given with repeat radiation therapy.
This study drug has been designed to block certain chemical pathways that stimulate tumor to grow. The study drug has been shown to slow the growth of a number of types of cancers.
This will be a dose escalation study. A dose escalation study means that successive groups of patients will receive higher doses of the study drug. There are three dose levels. The dose of the study drug received will depend on the stage the study has reached at the time a patient decides to participate.
In addition to taking the study drug patients will also receive radiation therapy to the brain tumor for 3 days.
Hypothesis The objective of this study is to determine the maximally tolerated dose (MTD) of VANDETANIB given with 36 Gy hypofractionated stereotactic radiotherapy. The MTD will be dose of VANDETANIB at which no patients develop acute grade 5 toxicity and less than 30% of patients develop acute (within 30 days of radiation therapy) or delayed (at least 30 days after radiation completed) dose limiting toxicities.
|Condition or disease||Intervention/treatment||Phase|
|Malignant Gliomas||Drug: Vandetanib Radiation: Fractionated Stereotactic Radiotherapy||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||13 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Dose Escalation Study of Vandetanib (ZACTIMA, ZD6474) With Hypofractionated Stereotactic Radiotherapy in Patients With Recurrent Malignant Gliomas|
|Study Start Date :||March 2007|
|Actual Primary Completion Date :||May 2010|
|Actual Study Completion Date :||January 2011|
Dose level 1:100 mg qd, 2:200 mg qd, 3:300 mg qd. Fractionated Stereotactic Radiotherapy: all patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd
Other Name: ZD6474, ZactimaRadiation: Fractionated Stereotactic Radiotherapy
All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
- Incidence of acute and delayed ≥ grade 3 Central nervous system (CNS) toxicity by Common Terminology Criteria (CTC) v.3. [ Time Frame: 12 months. ]
- Incidence of acute and delayed ≥ grade 3 non-CNS toxicity [ Time Frame: 12 months. ]
- Progression-free survival at 6 months [ Time Frame: 12 months. ]
- Overall survival [ Time Frame: 12 months. ]
- Objective response rate [ Time Frame: 12 months. ]
- Quality of survival [ Time Frame: 12 months. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00822887
|United States, Colorado|
|University of Colorado Health Science Center|
|Aurora, Colorado, United States, 80045|
|Principal Investigator:||Changhu Chen, MD||University of Colorado, Denver|